Effectiveness of high dose targeted radiation therapy in Gall bladder cancer.

EVALUATION OF SAFETY AND EFFICACY OF STEREOTACTIC BODY RADIOTHERAPY IN UNRESECTABLE GALL BLADDER CANCER: A PROSPECTIVE COHORT STUDY - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093569

Enrollment

Registered

2025-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C23- Malignant neoplasm of gallbladder

Interventions

Intervention1: Evaluation of efficacy and safety of stereotactic body radiotherapy-Prospective cohort study single arm in unresectable gall bladder cancer by volumetric arc therapy (VMAT) technique at

Eligibility

Inclusion criteria

Inclusion criteria: Patients with ECOG PS 0-2 histologically proven unresectable non metastatic gallbladder cancer

Exclusion criteria

Exclusion criteria: Patients with distant metastasis at presentation Prior radiotherapy, Pregnant patients. Bilirubin more than 5mg/Dl.Liver enzymes three times or more above the upper limit of normal. one or more than one comorbidities

Design outcomes

Primary

Measure	Time frame
Response assessment following SBRT as per RECIST 1.1 criteriaTimepoint: 6 weeks after completion of SBRT	—

Secondary

Measure	Time frame
Acute Gastrointestinal toxicity as per RTOG criteriaTimepoint: During treatment & till 6 weeks following SBRT;To assess resectability following SBRTTimepoint: After 6 weeks of SBRT	—

Countries

India

Contacts

Public ContactDr. Deepak Kumar Das

All India Institute of Medical Sciences, Bhubaneswar

radonc_deepak@aiimsbhubaneswar.edu.in7978760783

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026